



UCB S.A. Allée de la Recherche 60, B-1070 Brussels (Belgium)

Press Release

UCB sells its food diagnostics business to Neogen

Brussels (Belgium), July 6, 2005 – UCB announces that it has signed an agreement with Neogen Corporation (NASDAQ: NEOG) to sell UCB's dairy antibiotic testing business.

These activities represent a small part of UCB's global business and are considered non-core. This divestment is therefore in line with UCB's long-term vision to build a global biopharmaceutical leader bringing to specialists first, new medicines to treat patients suffering from severe diseases.

About UCB

UCB - www.ucb-group.com - is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specializing in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex™ (antitussive) and Metadate™ / Equasym XL™ (attention-deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries and achieved in 2004 revenues of € 2.1 billion (including net sales, royalties, and fees) and an operating profit before amortization (EBITA) of € 389 million (on a pro-forma IFRS basis including 12 months of Celltech and excluding the Surface Specialties activities, divested in February 2005). UCB is listed on Euronext Brussels with a market capitalization of approximately € 5.8 billion.

For further information, please contact

Jean-Christophe Donck

Vice President, Corporate Communications and Investor Relations

+32 2 559 9588

jc.donck@ucb-group.com